File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Book Chapter: Prostate Cancer

TitleProstate Cancer
Authors
KeywordsDecipher
DNA
DNA methylation
Germline genetics
Prolaris
RNA
Somatic genetic alterations
Issue Date2017
PublisherElsevier/Academic Press
Citation
Prostate Cancer. In David, SP (Eds.),Genomic and Precision Medicine: Primary Care (Third edition), p. 211-230. London: Elsevier/Academic Press, 2017 How to Cite?
AbstractIn personalized medicine (PM), the aim is to provide individual risk assessment for medical conditions, or to predict the efficacy of measures intended to monitor, prevent, or treat these conditions (. http://www.personalizedmedicinecoalition.org). The approaches of PM could be important in addressing clinical and public health issues involved in a variety of diseases, including cancers that are detected via population-level screening. This is particularly relevant to prostate cancer (PCa), where concerns have been raised regarding prostate-specific antigen screening, subsequent overdiagnosis of low-grade diseases, and ultimately overtreatment of many indolent cancers. These interrelated issues have prompted a significant effort to identify markers that can effectively differentiate individuals who have different risks for PCa onset or progression. Improved risk estimation may help to address this major public health problem, as the prostate is the most common site of cancer diagnosis, accounting for approximately 26% of all new cancer diagnoses and 9% of cancer deaths in US men. This translates to an estimated 220,800 PCa diagnoses and 27,540 deaths in US men each year (Siegel et al., 2015. CA Cancer J Clin).
Persistent Identifierhttp://hdl.handle.net/10722/314353
ISBN

 

DC FieldValueLanguage
dc.contributor.authorLiu, Wennuan-
dc.contributor.authorNa, Rong-
dc.contributor.authorConran, Carly-
dc.contributor.authorXu, Jianfeng-
dc.date.accessioned2022-07-20T12:03:44Z-
dc.date.available2022-07-20T12:03:44Z-
dc.date.issued2017-
dc.identifier.citationProstate Cancer. In David, SP (Eds.),Genomic and Precision Medicine: Primary Care (Third edition), p. 211-230. London: Elsevier/Academic Press, 2017-
dc.identifier.isbn9780128006856-
dc.identifier.urihttp://hdl.handle.net/10722/314353-
dc.description.abstractIn personalized medicine (PM), the aim is to provide individual risk assessment for medical conditions, or to predict the efficacy of measures intended to monitor, prevent, or treat these conditions (. http://www.personalizedmedicinecoalition.org). The approaches of PM could be important in addressing clinical and public health issues involved in a variety of diseases, including cancers that are detected via population-level screening. This is particularly relevant to prostate cancer (PCa), where concerns have been raised regarding prostate-specific antigen screening, subsequent overdiagnosis of low-grade diseases, and ultimately overtreatment of many indolent cancers. These interrelated issues have prompted a significant effort to identify markers that can effectively differentiate individuals who have different risks for PCa onset or progression. Improved risk estimation may help to address this major public health problem, as the prostate is the most common site of cancer diagnosis, accounting for approximately 26% of all new cancer diagnoses and 9% of cancer deaths in US men. This translates to an estimated 220,800 PCa diagnoses and 27,540 deaths in US men each year (Siegel et al., 2015. CA Cancer J Clin).-
dc.languageeng-
dc.publisherElsevier/Academic Press-
dc.relation.ispartofGenomic and Precision Medicine: Primary Care (Third edition)-
dc.subjectDecipher-
dc.subjectDNA-
dc.subjectDNA methylation-
dc.subjectGermline genetics-
dc.subjectProlaris-
dc.subjectRNA-
dc.subjectSomatic genetic alterations-
dc.titleProstate Cancer-
dc.typeBook_Chapter-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/B978-0-12-800685-6.00012-6-
dc.identifier.scopuseid_2-s2.0-85054266347-
dc.identifier.spage211-
dc.identifier.epage230-
dc.publisher.placeLondon-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats